No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Underweight generalists create multi-year biotech opportunity
The speaker argued that generalist portfolio managers are structurally 20% underweight biotech, creating a compelling entry point as capital markets heal and valuations hit multi-year lows.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.